Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

Fineline Cube May 19, 2026
Company Drug

Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC

Fineline Cube May 19, 2026
Company Drug

Asieris’ USP1 Inhibitor APL-2302 Cleared for Clinical Trials

Fineline Cube Jan 17, 2025

China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced receiving clinical clearance from the...

Company Drug

Zhejiang Huahai’s HB0056 Approved for US Phase I Asthma Trial

Fineline Cube Jan 17, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced receiving clinical trial approval from...

Company Drug

Hengrui’s HER2-Targeted ADC and Antibody Drug Combo Approved for Trials

Fineline Cube Jan 17, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical trial approval from...

Company Drug

CSPC’s SYS 6043 Receives FDA Approval for Clinical Trials

Fineline Cube Jan 17, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its in-house developed SYS 6043...

Company Drug

Innovent’s Limertinib Wins NMPA Approval for NSCLC Treatment

Fineline Cube Jan 17, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that it has received New Drug Application...

Company

ConjuStar Completes $15 Million Pre-A+ Financing Round

Fineline Cube Jan 17, 2025

ConjuStar, a clinical-stage biotechnology company based in Tianjin, China, has announced the completion of a...

Company Deals

Bio-Thera Solutions Licenses BAT2206 to World Medicine for Turkey

Fineline Cube Jan 16, 2025

On January 16, Bio-Thera Solutions Ltd (SHA: 688177), a science – driven innovative global biopharmaceutical...

Company Deals

GE Healthcare and Sutter Health Form $1B Care Alliance

Fineline Cube Jan 16, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has formed...

Company Drug

HutchMed’s Orpathys Approved for Expanded NSCLC Indication in China

Fineline Cube Jan 16, 2025

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the National Medical Products Administration...

Company Drug

Innovent’s IBI343 Receives Breakthrough Therapy Designation for Pancreatic Cancer

Fineline Cube Jan 16, 2025

China-based biopharma Innovent Biologics, Inc. (HKG: 1801) has announced receiving another Breakthrough Therapy Designation (BTD)...

Company Drug

Wepon Medical’s WP107 Receives FDA Approval for gMG Clinical Trial

Fineline Cube Jan 16, 2025

China-based Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced receiving clinical trial approval...

Company Drug

Fosun Pharma Initiates Phase II Study for Glomerular Disease Treatment

Fineline Cube Jan 16, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

Hengrui’s SHR-9839 Receives NMPA Clearance for Advanced Tumors

Fineline Cube Jan 16, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving clinical clearance from the...

Legal / IP

Chipscreen’s Epidaza Patent Faces Invalidation Request Review

Fineline Cube Jan 16, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has announced that a patent invalidation request...

Company Deals

Biogen Proposes to Acquire Sage Therapeutics for $469M

Fineline Cube Jan 15, 2025

US-based Sage Therapeutics, Inc. (NASDAQ: SAGE) has announced that it received an unsolicited, nonbinding proposal...

Company Deals Medical Device

Medtronic Secures Exclusive Distribution Rights for Contego’s Neuroguard and Excipio

Fineline Cube Jan 15, 2025

US-Irish firm Medtronic (NYSE: MDT) has entered into an exclusive distribution agreement with Contego Medical,...

Company Deals

Eli Lilly to Acquire Scorpion Therapeutics’ STX-478 for $2.5B

Fineline Cube Jan 15, 2025

US-based pharmaceutical giant Eli Lilly and Company (NYSE: LLY) is set to acquire STX-478 from...

Company Deals

Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B

Fineline Cube Jan 15, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of...

Company Deals

GSK Acquires IDRx for $1B to Boost GIST Treatment Pipeline

Fineline Cube Jan 15, 2025

UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has entered into an agreement with US-based biopharma IDRx, Inc....

Company Deals

Autobio Diagnostics Partners with Boditech Med for Korean IVD Market

Fineline Cube Jan 15, 2025

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with South Korea-headquartered...

Posts pagination

1 … 228 229 230 … 668

Recent updates

  • GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams
  • Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B
  • Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC
  • Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease
  • Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Company Drug

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.